Management of Hepatitis C Infection

  • Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/24/18 (What's New)

Summary

  • High SVR12 rates observed with 12 weeks of sofosbuvir/velpatasvir/voxilaprevir in phase III trials involving DAA-experienced patients

Action required